Photo taken from Agenus/LinkedIn
Sep 10, 2024, 13:38
Agenus‘s latest data from the clinical trial of BOT/BAL in refractory sarcomas at ESMO24
Agenus shared on LinkedIn:
“The Agenus team is headed to Barcelona for ESMO24.
This Friday, catch the latest data from our clinical trial of botensilimab and balstilimab in refractory sarcomas.
View the presentation details here.”
Proceed to video attached to post.
Source: Agenus/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 17, 2024, 23:36
Dec 17, 2024, 23:36
Dec 17, 2024, 23:36
Dec 17, 2024, 23:36
Dec 17, 2024, 23:36
Dec 17, 2024, 23:14
Dec 17, 2024, 23:14
Dec 17, 2024, 23:14